Your browser doesn't support javascript.
Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain.
Roel, Elena; Pistillo, Andrea; Recalde, Martina; Sena, Anthony G; Fernández-Bertolín, Sergio; Aragón, Maria; Puente, Diana; Ahmed, Waheed-Ul-Rahman; Alghoul, Heba; Alser, Osaid; Alshammari, Thamir M; Areia, Carlos; Blacketer, Clair; Carter, William; Casajust, Paula; Culhane, Aedin C; Dawoud, Dalia; DeFalco, Frank; DuVall, Scott L; Falconer, Thomas; Golozar, Asieh; Gong, Mengchun; Hester, Laura; Hripcsak, George; Tan, Eng Hooi; Jeon, Hokyun; Jonnagaddala, Jitendra; Lai, Lana Y H; Lynch, Kristine E; Matheny, Michael E; Morales, Daniel R; Natarajan, Karthik; Nyberg, Fredrik; Ostropolets, Anna; Posada, José D; Prats-Uribe, Albert; Reich, Christian G; Rivera, Donna R; Schilling, Lisa M; Soerjomataram, Isabelle; Shah, Karishma; Shah, Nigam H; Shen, Yang; Spotniz, Matthew; Subbian, Vignesh; Suchard, Marc A; Trama, Annalisa; Zhang, Lin; Zhang, Ying; Ryan, Patrick B.
  • Roel E; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Pistillo A; Universitat Autònoma de Barcelona, Spain.
  • Recalde M; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Sena AG; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Fernández-Bertolín S; Universitat Autònoma de Barcelona, Spain.
  • Aragón M; Janssen Research and Development, Titusville, New Jersey.
  • Puente D; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Ahmed WU; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Alghoul H; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Alser O; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Alshammari TM; Universitat Autònoma de Barcelona, Spain.
  • Areia C; NDORMS, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, United Kingdom.
  • Blacketer C; College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, United Kingdom.
  • Carter W; Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.
  • Casajust P; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Culhane AC; Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.
  • Dawoud D; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • DeFalco F; Janssen Research and Development, Titusville, New Jersey.
  • DuVall SL; Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Falconer T; Real-World Evidence, Trial Form Support, Barcelona, Spain.
  • Golozar A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gong M; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Hester L; Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Hripcsak G; Janssen Research and Development, Titusville, New Jersey.
  • Tan EH; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah.
  • Jeon H; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
  • Jonnagaddala J; Department of Biomedical Informatics, Columbia University, New York, New York.
  • Lai LYH; New York-Presbyterian Hospital, New York, New York.
  • Lynch KE; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
  • Matheny ME; Pharmacoepidemiology, Regeneron Pharmaceuticals, Westchester County, New York.
  • Morales DR; Digital Health China Technologies Co., Ltd., Beijing, China.
  • Natarajan K; Janssen Research and Development, LLC, Raritan, New Jersey.
  • Nyberg F; Department of Biomedical Informatics, Columbia University, New York, New York.
  • Ostropolets A; New York-Presbyterian Hospital, New York, New York.
  • Posada JD; Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.
  • Prats-Uribe A; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Gyeonggi-do, Republic of Korea.
  • Reich CG; School of Public Health and Community Medicine, UNSW Sydney, Kensington, Australia.
  • Rivera DR; School of Medical Sciences, University of Manchester, Manchester, United Kingdom.
  • Schilling LM; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah.
  • Soerjomataram I; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
  • Shah K; Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee.
  • Shah NH; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Shen Y; Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom.
  • Spotniz M; University of Southern Denmark, Odense, Denmark.
  • Subbian V; Department of Biomedical Informatics, Columbia University, New York, New York.
  • Suchard MA; New York-Presbyterian Hospital, New York, New York.
  • Trama A; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Zhang L; Department of Biomedical Informatics, Columbia University, New York, New York.
  • Zhang Y; Department of Medicine, School of Medicine, Stanford University, Redwood City, California.
  • Ryan PB; Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom.
Cancer Epidemiol Biomarkers Prev ; 30(10): 1884-1894, 2021 10.
Article in English | MEDLINE | ID: covidwho-1317085
ABSTRACT

BACKGROUND:

We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.

METHODS:

We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.

RESULTS:

We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range 5%-18% and 1%-14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events.

CONCLUSIONS:

Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. IMPACT This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Outcome Assessment, Health Care / COVID-19 / Neoplasms Type of study: Etiology study / Incidence study / Observational study / Prevalence study / Prognostic study / Risk factors Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America / Europa Language: English Journal: Cancer Epidemiol Biomarkers Prev Journal subject: Biochemistry / Epidemiology / Neoplasms Year: 2021 Document Type: Article Affiliation country: 1055-9965.EPI-21-0266

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Outcome Assessment, Health Care / COVID-19 / Neoplasms Type of study: Etiology study / Incidence study / Observational study / Prevalence study / Prognostic study / Risk factors Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America / Europa Language: English Journal: Cancer Epidemiol Biomarkers Prev Journal subject: Biochemistry / Epidemiology / Neoplasms Year: 2021 Document Type: Article Affiliation country: 1055-9965.EPI-21-0266